Navigation Links
OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
Date:1/4/2012

BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 4, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that data evaluating its investigational compound custirsen (OGX-011/TV-1011) in patients with advanced non-small cell lung cancer (NSCLC) were published in an early online version of the January 2012 issue of the Journal of Thoracic Oncology. These data provide additional clinical evidence for the potential of custirsen, a drug designed to block production of clusterin, a cell survival protein that is commonly overexpressed in several cancer types.

The single-arm trial, conducted at 15 sites in North America, evaluated treatment of custirsen in combination with a gemcitabine/platinum-based regimen in patients with previously untreated, advanced NSCLC. Eighty-one patients received at least one dose of custirsen and were included in the primary analysis. Key study findings are as follows:

  • The median overall survival was 14.1 months and progression-free survival was 4.3 months.
  • The one- and two-year survival rates were 54% and 30%, respectively; twelve percent of patients were still alive at a median follow-up of 41 months (range 38-59 months).
  • 69% of patients had a clinical response defined as objective response or stable disease and 31% of patients had tumor responses defined as complete or partial responses.
  • Custirsen treatment decreased serum clusterin levels in 95% of patients evaluated. In addition, patients who achieved a threshold minimum serum clusterin level of < / = 45 mcg/mL had a median survival of 27.1 months compared to 15.6 months for patients who did not.

The authors concluded that the survival data in this trial compared quite favorably with published data of patients receiving a gemcitabine/platinum-based regimen in a similar dose and schedule, with median survivals of approximately seven to 11 months. Additionally, t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
2. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
3. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
4. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
5. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
6. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
7. Echo Therapeutics Announces $3.6 Million Warrant Exercises
8. Shield HealthCare Announces Caregiver Story Contest Winners
9. PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer
10. Radient Pharmaceuticals Announces Reverse Stock Split
11. ViroPharma Announces Appointment of Julie H. McHugh to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Los beneficios y ganancias están por ... gasto en investigación y desarrollo   En ... septiembre de 2014) ZEISS aumentó sus ingresos en un ... anterior: 4.190 millones de euros) a pesar de los ... un 14 por ciento, a 360 millones de euros. ...
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3
...  InterMune, Inc. (NADSAQ: ITMN) today reported that ... its decision granting the additional benefit of ... of mild-to-moderate idiopathic pulmonary fibrosis (IPF).  Esbriet,s ... (not quantifiable benefit)  in the rating system ...
... Pharma Holdings, Inc. (NYSE AMEX: CPHI ) ("China ... China, today announced financial results for the year ended December ... , Revenue increased 9% to $81.2 million in fiscal ... , Income from operations was $22.0 million in fiscal year ...
Cached Medicine Technology:Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 2Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 3Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 4Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 5Esbriet® (pirfenidone) Benefit Granted by German Federal Joint Committee (G-BA) 6China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 2China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 3China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 4China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 5China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 6China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 7China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 8China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 9China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 10China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 11China Pharma Holdings, Inc. Reports Full Year 2011 Financial Results 12
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Attacks New York Department of ,Hype, with New York Times Ad ... (CCF) is running a full-page ad in the New York Times ... Department of Health,s hyperbolic "Don,t drink yourself fat" PSA campaign. The Center ... News and New York Post that ask New Yorkers, ...
... economic times, many business owners cut back and take a ... area cosmetic surgeon, has watched other cosmetic practices lock their ... conclusion that his medical spa and surgery center simply will ... to open another location in the ,Uptown, Dallas area. "I ...
... Oct. 1 Today, MSN released ... that helps people manage their health information on the Web. ... a variety of tools and widgets to upload, organize and ... The new service allows people to research medical concerns, read ...
... ... in stock, but supplies are expected to sell out quickly. Businesses and schools ... Purell on hand before the demand peaks as a result of the H1N1 ... company has 4.25 oz bottles, 12 oz pump bottles, 8 oz pump bottles ...
... ... the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , ... Englewood, CO (Vocus) October 1, ... unveiled the eleventh edition of the Biotech Beach™ Hotbed Campaign this morning. , , ...
... ... TCSterps On-Demand, a comprehensive Video Relay Interpreting (VRI) service providing Sign Language Interpreting ... ... -- TCS Associates , ( http://www.TCSassociates.com ) a total solutions provider for ...
Cached Medicine News:Health News:Consumer Group Continues Million Dollar Campaign Responding to NYC Health Officials' Hyperbolic PSA Campaign 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 2Health News:Beauty and the Economy: Unusual Timing for Dallas Uptown Medi-Spa Launch 3Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 2Health News:MSN Introduces Online Tools to Help People Make Smarter Health and Lifestyle Decisions 3Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 2Health News:Swine Flu Expected to Hit Hard - Purell Hand Sanitizer in Stock at CleanItSupply.com 3Health News:BioSpace Launches the 2010 Biotech Beach Hotbed Campaign 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 2Health News:TCS Associates: A Sign Language Interpreting Agency Launches New Video Remote Interpreting (VRI) Service called TCSterps On-Demand 3
Inquire...
... Captia™ Mumps IgG Enzyme- linked Immunosorbent Assay ... quantitative determination of IgG antibody to Mumps ... may be used for the determination of ... may be used to demonstrate seroconversion or ...
The DSL 05-10-MUM Mumps IgM Enzyme-Linked Immunosorbent Assay (ELISA) kit provides materials for the determination of IgM-class antibodies to Mumps virus in human serum. This assay is intended for in...
... of the TEG analyzer and the TEG analytical ... the formation and dissolution of the clot, showing ... ,Haemoscope's TEG analyzer is the only hemostasis analyzer ... and proven model developed by Prof. Helmut Hartert ...
Medicine Products: